e-Therapeutics Plc

“In-silico Drug Discovery Market” in terms of revenue was estimated to be worth $10.9 Bn in 2023 and is poised to reach $40.3 Bn by 2031, growing at a CAGR of 18.05% from 2024 to 2031 according to a new report by InsightAce Analytic. Market Analysis: One of the key elements anticipated to boost market expansion and demand is the increase in the amount of drug discovery data. Throughout the projection period, the market is also anticipated to increase as a result of the acceleration of growth in the biomarker identification field and the emphasis on lowering readmission and medical mistake rates. In addition, two important aspects that are anticipated to drive market expansion are the affordability and widespread use of in-silico drug designing services. Download Free Report Sample Pages: Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the in-silico drug discovery market are: Increasing Focus On Reducing Drug Errors Increasing Use Of Cloud-Based Software In Drug Discovery Rapid Technical Advancements In The Computational Biology Sector The following are the primary obstacles to the in-silico drug discovery market’s expansion: Lack Of Awareness About Safety And Health High Expense Of Techniques And Approaches High Levels Of Investment Are Required To Construct The Infrastructure For Healthcare Future expansion opportunities for the in-silico drug discovery market include: Growing Use Of Modern Biomarker Identification Tools Increasing Government Expenditures On R&D Growing Alliances And Partnerships Between Top Academic Institutions And Businesses Involved In Biotechnology And Pharmaceuticals Key Industry Insights & Findings from the Report: The industry is being propelled by technological advancements in computational biology, a growing emphasis on reducing prescription errors, and the expanding utilization of cloud-based technologies in the field of drug discovery. The globe in-silico drug discovery industry is driven by the growth of novel pharmacological compounds and the swift progression of computational biology technology. In 2023, North America controlled the market and contributed to the global revenue share. The largest share of the in-silico drug discovery market was occupied by preclinical experiments. An increasing number of entities are conducting preclinical trials for a variety of reasons, including the demand for more effective medications, the increasing complexity of diseases, and regulatory constraints. List of Prominent Players in the In-silico Drug Discovery Market: Aragen Life Sciences Pvt. Ltd. Curia Global, Inc. Certara, USA. Charles River Chemical Computing Group ULC. Collaborative Drug Discovery Inc. Dassault Systemes e-therapeutics plc. Evotec Insilico Medicine Ligand Pharmaceuticals Incorporated Numerate, Inc. PerkinElmer Inc. Schrödinger, Inc. Selvita Simulations Plus Tracxn Technologies WuXi AppTec Others Recent Developments: January 2022: Insilico Medicine formed a partnership with Fosun Pharma, a Chinese healthcare provider. To generate a new therapeutic portfolio, Insilico's AI-driven, end-to-end drug discovery platforms will be integrated with the clinical development and marketing expertise of Fosun Pharma. April 2021: The E.U. funded the Italian startup InSilicoTrials Technologies' 3 Horizon 2020 project, which aims to use in silico trials to support the development of cutting-edge medical technologies. Future market expansion for computer simulation trials for medical devices is anticipated to benefit from such initiatives. October 2020: The cloud-based software platform for enhancing and automating the biological processes of the enzyme-linked immunosorbent test (ELISA) has been launched by Synthace Ltd. Researchers are now able to create and run automated ELISA protocols with flexibility thanks to the Software Antha. In-silico Drug Discovery Market Dynamics: Market Drivers: Growing Usage of Cloud-Based Software The growing use of cloud technologies is driving the in-silico drug discovery sector. Pharmaceutical researchers can grow their computing environment as needed owing to cloud computing, which gives them access to nearly infinite processing resources. Organizations can more easily adapt solutions to meet their requirements. For instance, B.T.'s Cloud Compute life sciences platform can offer particular pharmaceutical applications from discovery to commercial operations, ensuring that the necessary applications function across pipelines rather than requiring all pipeline teams to use the same application. By allowing drug developers to examine past data as part of their clinical research operations, these tools boost overall productivity and lower the risk of clinical failure. Challenges: Limited Time For Analysis The market for in-silico drug discovery is only constrained by its brief duration. This approach has analysis periods ranging from tens to hundreds of nanoseconds, and it is computationally demanding depending on the size of the stimulated systems. This is problematic because the time interval, which can be anywhere from milliseconds to seconds, is often too brief to detect protein folding. This may lead to an inadequate sampling of protein conformations as a result. North America is Expected to Grow with the Highest CAGR During the Forecast Period In North America, the in-silico drug discovery market is likely to register a significant revenue share and develop at a rapid CAGR over the forecast period. This is explained by the critical need for therapies for uncommon illnesses like Lou Gehrig's disease and cystic fibrosis. Furthermore, U.S. biopharmaceutical businesses are spending more on research and development. U.S. investments in R&D and medicine reached over $250 billion in 2020. The growth of the industry can also be attributed to a more advanced network between manufacturers and service providers than in any other area. Additionally, the U.S. FDA's assistance has cleared up a number of concerns regarding the co-development process and contributed to the creation of a flexible regulatory pathway. The market is also being driven by the existence of strong vendors, technological advancements, an increase in the number of patients with a range of infectious and chronic diseases, and a growing government focus on enhancing the healthcare system. Segmentation of In-silico Drug Discovery Market- By Product Software Software-as-a-Service (SaaS) Consultancy-as-a-Service By Workflow Discovery Target Identification Bioinformatics Reverse Docking Protein Structure Prediction Target Validation Lead Discovery Library Design Pharmacophore Preclinical Tests Clinical Trials By Technology Artificial Intelligence Graphics Processing Unit (GPU) Other Technologies In-Silico Fishing RNN for Drug Design By Software Type Molecular modelling and de novo drug design software Pharmacophore Modelling software By End User Contract Research Organizations Pharmaceutical and Biopharmaceutical Companies Academic and Research Institutes Others By Region- North America- The US Canada Mexico Europe- Germany The UK France Italy Spain Rest of Europe Asia-Pacific- China Japan India South Korea South East Asia Rest of Asia Pacific Latin America- Brazil Argentina Rest of Latin America Middle East & Africa- GCC Countries South Africa Rest of Middle East and Africa Talk with Experts Panel on the In-silico Drug Discovery Market Report @ Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com

Talkspace, Teladoc and BetterHelp Amongst Winners of Second Annual Awards Celebrating Top Platforms for Mental Health Support NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Verywell Mind announced today its second annual Online Therapy Awards, honoring the 16 best digital services and directories transforming the way people seek mental health care. The Verywell Mind Online Therapy Awards are a comprehensive and proprietary analysis of digital therapy platforms, designed to help readers find options that suit their individual needs and serve as a starting point for anyone who may not know where to begin. Continue Reading Verywell Mind 2022 Online Therapy Awards Verywell Mind evaluated 55 online therapy companies and 25 therapist directories, as well as surveyed over 10,000 therapy users on top criteria they consider when choosing a service, including affordability, credibility, accessibility and user satisfaction. A special emphasis was placed on companies that offer inclusive support and those that service therapy deserts, making therapy more inclusive and attainable for all. The process for testing and analyzing nominees was created by Verywell Mind editors with guidance from mental health experts Amy Marschall, PsyD, Nic Hardy, PhD, LCSW, and Hannah Owens, LMSW, who helped evaluate and test each service. "As the COVID-19 pandemic has regressed, interest in teletherapy has remained. There are many teletherapy options and sometimes, the search for the best service to match an individual's needs can feel overwhelming," said Amy Morin, LCSW, editor-in-chief, Verywell Mind. "That's why we specialized our Online Therapy Awards to provide the right recommendations across a spectrum of need and provide a trusted guide for anyone seeking care." The winners of the 2022 Verywell Mind Online Therapy Awards include: Best Large Service – Talkspace Best Small Service – E-Therapy Cafe Best for Anxiety & Depression – Brightside Best Availability – BetterHelp Best for Psychiatry – Talkiatry Best for Relationships – ReGain Best for Accessibility – LiveHealth Online Best for Flexibility – Thriveworks Best for Kids & Family Therapy – Little Otter Best With Insurance – Teladoc Best for LGBTQIA+ – National Queer & Trans Therapists of Color Network Best for Black Communities – Therapy for Black Girls Best Comprehensive Care – MDLIVE Best Directory – Good Therapy Best Matching Service – Two Chairs Best for Group Therapy – Circles For more information on the Verywell Mind Online Therapy Awards and to read more about the list of winners, visit here. About Verywell Mind Verywell Mind is one of the largest mental health sites in the world, serving 6 million people a year during their moments of need. The award-winning publication is committed to providing inclusive mental health information through thousands of expert-written, medically-reviewed articles across hundreds of topics and empowers readers to get the mental health treatment they deserve. Verywell Mind is part of the Dotdash Meredith publishing family. SOURCE Verywell

Dublin, April 06, 2020 (GLOBE NEWSWIRE) -- The "Global AI-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering. This report projects the market to grow at a significant CAGR of 24.88% during the forecast period from 2019 to 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities. Despite the benefits of these software solutions, the major challenges in the market are lack of regulations and ethical issues. Some of the major opportunities for the key vendors in the market could be investment opportunities in emerging economies such as India, China, and Brazil and the introduction of systems in different languages. Expert Quote Biopharmaceutical companies are the major end-users of the AI-enabled drug discovery and clinical trials market in terms of revenue share. The biopharmaceutical companies' market share is expected to increase by up to $2,692.8 million. However, the usage of the solutions is expected to increase in contract research organizations and academic & research centers in order to streamline the workflow of the facilities and improve the quality of care. Market Segmentation The Global AI-Enabled Drug Discovery and Clinical Trials Market can be segmented on the basis of component type, application, therapeutic application, end-user, and region. As of 2018, AI-enabled solutions accounted for $207.5 million and is expected to reach a value of $3,385 million by the end of 2030. In terms of growth, the end-users and academic institutes and research centers segment is expected to grow at the highest CAGR of 25.45% during the forecast period. As of 2018, North America is the largest shareholder for the overall market and is expected to reach a value of $2,460.5 million by the end of 2030, growing with a CAGR of 24.47% during the forecast period. However, a higher growth rate can be expected from the Asia-Pacific region, considering its improving healthcare infrastructure, overburdened healthcare system, and the focus of ASEAN countries to be recognized as a medical tourism destination. Although the adoption rate of the AI-enabled solutions has been moderate, the potential that lies in them is immense. The integration of AI-enabled solutions in the healthcare facility will not only enhance medical research but also help research organizations in cost containment. To make the entire drug discovery and development process more efficient, the AI-enabled solutions can be integrated across various stakeholders, namely biopharmaceutical companies, contract research organizations (CROs), academic institutes, and research centers. Key Companies Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X Discovery Holdings, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, and Concerto HealthAI. Research Highlights Biopharmaceutical companies are expected to be the major end-users of AI-enabled solutions and services during the forecast period. Contract research organizations (CROs) and academic institutes and research centers are expected to see the highest growth rate during the forecast period. The use of AI-enabled solutions and services in drug discovery and development can significantly improve the candidate selection process and data analysis process. North America is expected to be the major market shareholder of the market, followed by Europe, Asia-Pacific, and Rest-of-the-World. While Asia-Pacific is expected to see the highest growth rate, the CAGR for Rest-of-the-Word is expected to be close to Asia-Pacific. The market is in the nascent stage of development and hence is a blend of more than 100 companies. The key regional players are expected to evolve as global leaders for the market. Key Questions Answered in the Report How can AI integration in drug discovery and clinical trials decrease drug development expenditure? How are pharmaceutical/biopharmaceutical companies assisting in market development? How can regulatory bodies such as FDA accelerate the AI adoption within the drug discovery and development process? What is the present status of AI adoption in the drug discovery and development processes globally? Which companies are expected to emerge as the key players in the market? How are the companies operating in the market generating revenue? What are the key regulatory implications in developed and developing regions for AI-enabled drug discovery and clinical trials market? How can the companies expand in non-English speaking regions? Which therapeutic area (such as oncology and neurology) has the highest AI adoption rate in clinical trials? Which region is anticipated to serve as an emerging market for drug discovery and clinical trials, respectively? What is the state of AI adoption in the Middle East and Latin America? What are the different methodologies followed by the companies in the market for drug development? Key Topics Covered Executive Summary 1 Product Definition 1.1 Inclusion and Exclusion 2 Scope of the Report 2.1 Scope of the Study 2.2 Key Questions Answered in the Report 3 Research Methodology 3.1 Primary Data Sources 3.2 Secondary Data Sources 3.3 Market Estimation Model 3.4 Companies Profiled 3.5 Assumptions and Limitations 4 Industry Analysis 4.1 Industry Trends 4.1.1 Incorporation Trends 4.2 Value Analysis 4.2.1 Drug Discovery 4.2.2 Clinical Trials 4.3 Regulatory Framework and Government Initiatives 4.3.1 Regulatory Framework in North America 4.3.2 Regulatory Framework in Europe 4.3.3 Government Initiatives 4.3.3.1 Government Initiatives in North America 4.3.3.2 Government Initiatives in Europe 5 Pipeline Analysis 6 Competitive Landscape 6.1 Key Developments and Strategies 6.1.1 Collaborations and Partnerships 6.1.2 Funding 6.1.3 Product Launch and Upgradation 6.1.4 Mergers and Acquisitions 6.1.5 Others 6.2 Business Model Analysis 6.2.1 Subscription 6.2.2 Software as a Service and Platform as a Service (SaaS and PaaS) 6.2.3 Pay Per Use Model 6.3 Competitive Benchmarking 7 Market Dynamics 7.1 Market Drivers 7.1.1 Increasing Drug Development Expenditure 7.1.2 Facilitation of Polypharmacology 7.1.3 Growing Number of Synergistic Activities 7.2 Market Restraints 7.2.1 Lack of Regulations 7.2.2 Ethical Issues 7.3 Market Opportunities 7.3.1 Expansion of Business in Developing Economies such as India and Brazil 7.3.2 Introduction of Solutions in Different Languages 8 Global AI-enabled Drug Discovery and Clinical Trials Market 8.1 Assumptions and Limitations 8.2 Key Findings and Opportunity Assessment 8.2.1 Key Findings 8.2.2 Opportunity Assessment 9 Global AI-enabled Drug Discovery and Clinical Trials Market (by Component) 9.1 Overview 9.2 Solutions 9.3 Services 10 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application) 10.1 Overview 10.2 Data Aggregation and Analysis 10.3 Clinical Trials 10.4 Drug Design 10.5 Drug Characterization 10.6 Biomarker Research 11 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Therapeutic Applications) 11.1 Overview 11.2 Oncology 11.3 Cardiovascular Diseases 11.4 Nervous System Diseases 11.5 Respiratory Disorder 11.6 Metabolic Diseases 11.7 Immunologic Diseases 11.8 Infectious Diseases 11.9 Others 12 Global AI-Enabled Drug Discovery and Clinical Trials Market (by End User) 12.1 Overview 12.2 Biopharmaceutical Industry 12.3 Contract Research Organizations (CROs) 12.4 Academic Institutes and Research Centers 13 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region) 13.1 Overview 13.2 North America 13.2.1 U.S. 13.2.2 Canada 13.3 Europe 13.3.1 Germany 13.3.2 U.K. 13.3.3 France 13.3.4 Italy 13.3.5 Spain 13.3.6 Rest-of-Europe 13.4 Asia-Pacific 13.4.1 China 13.4.2 Japan 13.4.3 South Korea 13.4.4 Australia 13.4.5 India 13.4.6 Rest-of-Asia-Pacific 13.5 Rest-of-the-World 14 Company Profiles 14.1 Accutar Biotechnology Inc. 14.1.1 Company Overview 14.1.2 Role of Accutar Biotechnology in the Global AI-Enabled Drug Discovery and Clinical Trials Market 14.1.3 SWOT Analysis 14.2 AiCure, LLC 14.3 Ardigen 14.4 Atomwise, Inc. 14.5 BenevolentAI 14.6 Berg LLC 14.7 Berkeley Lights, Inc. 14.8 BioAge Labs, Inc. 14.9 Biovista Inc. 14.10 C4X Discovery Holdings PLC 14.11 Clinithink Ltd. 14.12 Cloud Pharmaceuticals, Inc. 14.13 Cyclica, Inc. 14.14 CytoReason 14.15 Symphony Innovation, LLC 14.16 Deep Genomics Inc. 14.17 DeepThink Health Inc. 14.18 Envisagenics, Inc. 14.19 Exscientia Limited 14.20 e-therapeutics PLC 14.21 GNS Healthcare 14.22 Insilico Medicine 14.23 Lantern Pharma Inc. 14.24 Medable, Inc. 14.25 Mind the Byte 14.26 NuMedii, Inc. 14.27 Nuritas, Ltd. 14.28 Owkin, Inc. 14.29 Recursion Pharmaceuticals, Inc. 14.30 Schrdinger, LLC 14.31 TARA Biosystems, Inc. 14.32 twoXAR, Incorporated 14.33 Verge Analytics, Inc. 14.34 Winterlight Labs Inc. 14.35 WuXi Nextcode Genomics 14.36 XtalPi Inc. For more information about this report visit Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900